Abstract: Provided is a conjugate comprising a ligand, a spacer, and a peptide linker useful for an in-vivo diagnostic drug and internal radiation therapy, using an anti-human MUC1 antibody Fab fragment whose binding activity is not attenuated even by labeling with a metal, a fluorescent dye, or the like. A conjugate comprising 3arm DOTA, a specific spacer, a specific peptide linker, and a biomolecule including an anti-human MUC1 antibody Fab fragment, wherein the binding activity thereof is not attenuated even by labeling with a metal, a fluorescent dye, or the like, can be used as a diagnostic composition and/or a pharmaceutical composition.

Abstract: Provided is a conjugate comprising a ligand, a spacer, and a peptide linker useful for an in-vivo diagnostic drug and internal radiation therapy, using an anti-human CEACAM5 antibody Fab fragment whose binding activity is not attenuated even by labeling with a metal, a fluorescent dye, or the like. A conjugate comprising an anti-human CEACAM5 antibody Fab fragment and a ligand, the fragment comprising a heavy chain fragment including a heavy chain variable region consisting of a specific amino acid sequence and a light chain including a light chain variable region consisting of a specific amino acid sequence, or a conjugate comprising a ligand, a spacer, and a peptide linker, wherein the binding activity thereof is not attenuated even by labeling with a metal, a fluorescent dye, or the like, can be used as a diagnostic composition and/or a pharmaceutical composition.

Abstract: Provided are a conjugate comprising an anti-human MUC1 antibody Fab fragment and a peptide linker and/or a ligand, a composition for diagnosis and/or a pharmaceutical composition comprising the conjugate, a method for diagnosing and/or treating a cancer using the conjugate, and the like. In the conjugate used, the anti-human MUC1 antibody Fab fragment is bound to the ligand via the peptide linker or the like.

Abstract: It was found that a new fusion gene of a portion of the KIF5B gene and a portion of the RET gene, which is present in a portion of cancer patients, is a gene responsible for cancer. Based on this finding, detection methods of a polynucleotide as the gene and a polypeptide encoded by the polynucleotide were established. The detection methods involve detecting a fusion gene of a portion of the KIF5B gene and a portion of the RET gene, or a fusion protein encoded by such a fusion gene. The primer sets and the detection kits comprise sense primers designed from a portion encoding KIF5B and antisense primers designed from a portion encoding RET.

Abstract: A screening tool and a screening method of a substance which is useful as an agent for improving the memory, an agent for improving learning ability, and/or an antidementia agent; a polypeptide, a polynucleotide, a vector, and a cell which may be used in the above screening; and a novel agent for improving the memory, a novel agent for improving learning ability, and/or a novel antidementia agent are disclosed. The above screening tool is composed of a calcium-permeable nonselective cation channel or a cell expressing the channel.

Abstract: A novel polypeptide which is useful in searching for a therapeutic agent for diabetes, a polynucleotide encoding the polypeptide, an expression vector comprising the polynucleotide, a cell transfected with the expression vector, an antibody binding to the polypeptide, and a method of screening a therapeutic agent for diabetes are disclosed. The polypeptide is a novel background potassium channel expressed in the pancreas.

Abstract: There is provided a method of screening for substance that inhibits cell death induced by activation of PARP, particularly a substance that is useful as a therapeutic and/or preventive agent for rheumatoid arthritis, neuronal death at the time of cerebral ischemia, cell death of the heart after myocardial infarction reperfusion, autoimmune destruction of ?-cells of pancreatic islets of Langerhans, cell death after shock, or inflammatory reaction by immunocyte death. Also provided are a novel protein and a novel gene encoding the same. The aforementioned screening method comprises a step of allowing a test substance to contact a cell expressing an LTRPC2 protein under a conditions such that the LTRPC2 protein can be activated, and a step of analyzing inhibition of LTRPC2 protein activation. The aforementioned novel protein is a rat or mouse LTRPC2 protein, and the aforementioned novel gene is a rat or mouse LTRPC2 gene.

Abstract: A screening tool and a screening method of a substance which is useful as an agent for improving the memory, an agent for improving learning ability, and/or an antidementia agent; a polypeptide, a polynucleotide, a vector, and a cell which may be used in the above screening; and a novel agent for improving the memory, a novel agent for improving learning ability, and/or a novel antidementia agent are disclosed. The above screening tool is composed of a calcium-permeable nonselective cation channel or a cell expressing the channel.

Abstract: There is provided a method for screening a substance capable of inhibiting cell death induced by the activation of PARP, particularly a substance which is useful as a therapeutic agent and/or a preventive agent for rheumatoid arthritis, neuronal death at the time of cerebral ischemia, cell death of the heart after myocardial infarction reperfusion, autoimmune destruction of &bgr;-cells of pancreatic islets of Langerhans, cell death after shock, or inflammatory reaction by immunocyte death. Also provided are a novel protein and a novel gene coding for the same.

Abstract: A novel polypeptide which is useful in searching for a therapeutic agent for diabetes, a polynucleotide encoding the polypeptide, an expression vector comprising the polynucleotide, a cell transfected with the expression vector, an antibody binding to the polypeptide, and a method of screening a therapeutic agent for diabetes are disclosed.

Abstract: A novel polypeptide, a polynucleotide encoding the polypeptide, an expression vector comprising the polynucleotide, a cell transfected with the expression vector, an antibody binding to the polypeptide, a method for screening an agent for suppressing the polypeptide, a method for screening an antiobestic agent, and a process for producing the polypeptide are disclosed.